Schéma : Primary objective: Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with oxaliplatin + EGFR.
- Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall survival rate and the objective response rate.
- Evaluate the tolerance profile of aflibercept in combination with FOLFIRI.
- Observational study, national, multicenter, cohort, prospective without intervention on the therapeutic strategy.
Phase : NA
Stade : Localement avancé à Métastatique